Abstract
Since bortezomib was approved by the US Food and Drug Administration as the first proteasome inhibitor for the treatment of multiple myeloma (MM) ten years ago, proteasome inhibition has been established as an effective MM treatment strategy. However, some limitations have been found with bortezomib-based therapies, including bortezomib resistance (both intrinsic and acquired), severe toxicities (such as peripheral neuropathy), and unsatisfied efficacy in the treatment of solid tumors. In order to overcome the shortcomings of bortezomib, researchers have investigated the involved molecular mechanisms and developed novel strategies to improve proteasome inhibitor-based therapies and patient cares. This mini hot issue will review the current advances in the status of bortezomib, clinically tested second generation proteasome inhibitors, and preclinically developed proteasome inhibitors, and summarize some cutting-edge strategies in this field, including selective targeting immunoproteasomes, 19S deubiquitinases or ubiquitin E3 ligases, and developing novel combinational therapies. While there are still many new challenges ahead, the great progress in proteasome inhibitor therapy will definitely help illuminate the bright future of MM and other cancer management.
Current Cancer Drug Targets
Title:Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies)
Volume: 14 Issue: 6
Author(s): Q. Ping Dou
Affiliation:
Abstract: Since bortezomib was approved by the US Food and Drug Administration as the first proteasome inhibitor for the treatment of multiple myeloma (MM) ten years ago, proteasome inhibition has been established as an effective MM treatment strategy. However, some limitations have been found with bortezomib-based therapies, including bortezomib resistance (both intrinsic and acquired), severe toxicities (such as peripheral neuropathy), and unsatisfied efficacy in the treatment of solid tumors. In order to overcome the shortcomings of bortezomib, researchers have investigated the involved molecular mechanisms and developed novel strategies to improve proteasome inhibitor-based therapies and patient cares. This mini hot issue will review the current advances in the status of bortezomib, clinically tested second generation proteasome inhibitors, and preclinically developed proteasome inhibitors, and summarize some cutting-edge strategies in this field, including selective targeting immunoproteasomes, 19S deubiquitinases or ubiquitin E3 ligases, and developing novel combinational therapies. While there are still many new challenges ahead, the great progress in proteasome inhibitor therapy will definitely help illuminate the bright future of MM and other cancer management.
Export Options
About this article
Cite this article as:
Dou Ping Q., Editorial (Thematic Issue: Recent Advances in Proteasome Inhibitor-Based Cancer Therapies), Current Cancer Drug Targets 2014; 14 (6) . https://dx.doi.org/10.2174/1568009614666140805163018
DOI https://dx.doi.org/10.2174/1568009614666140805163018 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The ARRONAX Project
Current Radiopharmaceuticals The Pim Kinases: New Targets for Drug Development
Current Drug Targets Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine Subject Index To Volume 5
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Nucleoside Transport in the Antineoplastic Activity of Purine Nucleoside Chemotherapeutic Agents
Current Cancer Therapy Reviews The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Subject Index To Volune 2
Current Cancer Therapy Reviews Nonprofit Pharma: Solutions to What Ails the Industry
Current Medicinal Chemistry Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology NFκB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry The Epidemiology of Sepsis
Current Pharmaceutical Design